MCID: BNM001
MIFTS: 52

Bone Marrow Cancer

Categories: Cancer diseases, Immune diseases, Bone diseases, Blood diseases

Aliases & Classifications for Bone Marrow Cancer

MalaCards integrated aliases for Bone Marrow Cancer:

Name: Bone Marrow Cancer 12 14
Malignant Neoplasm of Bone Marrow 12 69
Myeloproliferative Disorders 41
Malignant Bone Marrow Tumor 12
Myeloproliferative Disease 69
Bone Marrow Neoplasms 69
Bone Marrow Neoplasm 12
Bone Marrow Tumor 12

Classifications:



External Ids:

Disease Ontology 12 DOID:4960
ICD10 32 D47.1
MeSH 41 D009196

Summaries for Bone Marrow Cancer

Disease Ontology : 12 A hematopoietic cancer that derives from the blood-forming stem cells of the bone marrow.

MalaCards based summary : Bone Marrow Cancer, also known as malignant neoplasm of bone marrow, is related to myeloproliferative neoplasm and juvenile myelomonocytic leukemia. An important gene associated with Bone Marrow Cancer is JAK2 (Janus Kinase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Peginterferon alfa-2b and Hydroxyurea have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Bone Marrow Cancer

Diseases related to Bone Marrow Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 80)
# Related Disease Score Top Affiliating Genes
1 myeloproliferative neoplasm 32.9 ABL1 BCR FGFR1 JAK2 MPL PDGFRA
2 juvenile myelomonocytic leukemia 32.0 FLT3 JAK2 PDGFRA PDGFRB PTPN11 RUNX1
3 myelofibrosis 30.6 CD177 CSF3 EPO FLT3 GATA1 IL3
4 leukemia, chronic myeloid 30.5 ABL1 BCR CD177 CSF3 EPO FLT3
5 myelodysplastic syndrome 29.9 ABL1 CSF3 EPO EPOR FLT3 GATA1
6 myeloproliferative disorder, chronic, with eosinophilia 12.4
7 pdgfrb-associated chronic eosinophilic leukemia 11.5
8 ocular cancer 10.9
9 papular mucinosis 10.9
10 thrombocytopenia 3 10.6 MPL THPO
11 acute myeloblastic leukemia with maturation 10.6 FLT3 KIT
12 philadelphia-negative chronic myeloid leukemia 10.6 ABL1 BCR
13 deep leiomyoma 10.6 CD177 KIT
14 splenomegaly 10.6 EPO JAK2 MPL
15 cellular neurofibroma 10.6 ABL1 PDGFRB
16 thrombocythemia 1 10.6 MPL THPO
17 amegakaryocytic thrombocytopenia, congenital 10.6 IL3 MPL THPO
18 dyskeratosis congenita, autosomal dominant 6 10.5 MPL THPO
19 acquired polycythemia 10.5 EPO EPOR JAK2
20 neonatal leukemia 10.5 FLT3 GATA1 PTPN11
21 reticular perineurioma 10.5 KIT PDGFRA
22 acute myeloid leukemia with t(8;21)(q22;q22) translocation 10.5 FLT3 KIT RUNX1
23 budd-chiari syndrome 10.5 JAK2 MPL PDGFRA
24 retinitis pigmentosa and erythrocytic microcytosis 10.5 EPO GATA1 IL3 JAK2
25 primary hypereosinophilic syndrome 10.5 FGFR1 PDGFRA PDGFRB
26 desmoid tumor 10.5 KIT PDGFRA PDGFRB
27 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 10.5 FLT3 KIT RUNX1
28 acute erythroid leukemia 10.5 EPO EPOR GATA1 JAK2
29 heart sarcoma 10.4 KIT PDGFRA PDGFRB
30 fibrosarcoma of bone 10.4 KIT PDGFRA PDGFRB
31 blood coagulation disease 10.4 CSF3 JAK2 MPL THPO
32 myelophthisic anemia 10.4 JAK2 PTPN11
33 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 10.4 FGFR1 JAK2 PDGFRA PDGFRB
34 thrombocytopenia-absent radius syndrome 10.4 FGFR1 GATA1 JAK2 MPL THPO
35 childhood leukemia 10.4 ABL1 PTPN11 RUNX1
36 mast cell disease 10.4 KIT PDGFRA PDGFRB
37 primary polycythemia 10.4 EPO EPOR IL3 JAK2
38 pancytopenia 10.4 CSF3 EPO MPL THPO
39 thrombocytosis 10.4 EPO IL3 JAK2 MPL THPO
40 thrombocytopenia 10.4 CSF3 GATA1 MPL THPO
41 leiomyosarcoma 10.4 KIT PDGFRA PDGFRB
42 hypereosinophilic syndrome, idiopathic 10.4 IL3 KIT PDGFRA PDGFRB
43 severe congenital neutropenia 10.3 CSF3 IL3 JAK2 PTPN11
44 ewing's family of tumors 10.3 CSF3 EPO EPOR KIT
45 refractory anemia 10.3 EPO IL3 JAK2 MPL RUNX1
46 megakaryocytic leukemia 10.3 GATA1 IL3 JAK2 RUNX1 THPO
47 neurofibromatosis, type iv, of riccardi 10.3 KIT PDGFRA PTPN11
48 systemic mastocytosis 10.3 FGFR1 JAK2 KIT PDGFRA PDGFRB
49 chronic myelomonocytic leukemia 10.3 FLT3 JAK2 KIT PDGFRB RUNX1
50 immune system disease 10.3 CSF3 EPO IL3 JAK2 THPO

Graphical network of the top 20 diseases related to Bone Marrow Cancer:



Diseases related to Bone Marrow Cancer

Symptoms & Phenotypes for Bone Marrow Cancer

GenomeRNAi Phenotypes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

25 (show all 40)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00173-A 9.98 PDGFRA FLT3
2 Decreased viability GR00221-A-1 9.98 PDGFRA PDGFRB ABL1 FGFR1 FLT3 KIT
3 Decreased viability GR00221-A-2 9.98 ABL1 FGFR1
4 Decreased viability GR00221-A-3 9.98 PDGFRA PDGFRB ABL1
5 Decreased viability GR00221-A-4 9.98 PDGFRA PDGFRB FLT3
6 Decreased viability GR00301-A 9.98 KIT
7 Decreased viability GR00342-S-1 9.98 PDGFRB ABL1
8 Decreased viability GR00342-S-2 9.98 ABL1
9 Decreased viability GR00342-S-3 9.98 ABL1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.88 ABL1 FGFR1 BCR
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.88 ABL1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.88 CSF3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-115 9.88 BCR
14 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.88 BCR
15 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.88 ABL1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-124 9.88 BCR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.88 FGFR1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-126 9.88 FGFR1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.88 ABL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.88 ABL1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.88 BCR
22 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.88 BCR
23 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.88 FGFR1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-183 9.88 FGFR1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-2 9.88 BCR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-215 9.88 BCR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-29 9.88 BCR
28 Increased shRNA abundance (Z-score > 2) GR00366-A-3 9.88 ABL1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.88 ABL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.88 FGFR1 ABL1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-45 9.88 CSF3
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.88 ABL1 FGFR1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-50 9.88 FGFR1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-6 9.88 CSF3
35 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.88 FGFR1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.88 CSF3 FGFR1 ABL1 BCR
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.88 ABL1 BCR
38 Decreased substrate adherent cell growth GR00193-A-1 9.7 KIT
39 Decreased substrate adherent cell growth GR00193-A-2 9.7 ABL1 KIT
40 Decreased substrate adherent cell growth GR00193-A-4 9.7 ABL1 FGFR1 FLT3 KIT

MGI Mouse Phenotypes related to Bone Marrow Cancer:

43 (show all 15)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.43 JAK2 FLT3 KIT GATA1 PTPN11 PDGFRA
2 cellular MP:0005384 10.41 JAK2 FLT3 KIT GATA1 MPL PTPN11
3 immune system MP:0005387 10.39 JAK2 FLT3 KIT GATA1 MPL PTPN11
4 homeostasis/metabolism MP:0005376 10.36 JAK2 FLT3 KIT GATA1 MPL PTPN11
5 growth/size/body region MP:0005378 10.34 FGFR1 JAK2 FLT3 KIT GATA1 PDGFRB
6 embryo MP:0005380 10.3 JAK2 KIT GATA1 MPL PTPN11 PDGFRA
7 cardiovascular system MP:0005385 10.25 GATA1 FGFR1 KIT PDGFRB PTPN11 PDGFRA
8 mortality/aging MP:0010768 10.22 FGFR1 JAK2 FLT3 KIT GATA1 MPL
9 endocrine/exocrine gland MP:0005379 10.21 FGFR1 JAK2 FLT3 KIT PDGFRB PTPN11
10 integument MP:0010771 10.14 FGFR1 JAK2 KIT GATA1 PTPN11 PDGFRA
11 liver/biliary system MP:0005370 10.07 JAK2 KIT GATA1 PTPN11 RUNX1 STAT5A
12 normal MP:0002873 9.97 JAK2 KIT GATA1 PTPN11 PDGFRA RUNX1
13 no phenotypic analysis MP:0003012 9.8 FGFR1 FLT3 KIT PTPN11 PDGFRA RUNX1
14 respiratory system MP:0005388 9.56 KIT GATA1 PTPN11 PDGFRA RUNX1 EPO
15 skeleton MP:0005390 9.36 FGFR1 JAK2 FLT3 KIT GATA1 PDGFRB

Drugs & Therapeutics for Bone Marrow Cancer

Drugs for Bone Marrow Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 167)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 215647-85-1, 99210-65-8
2
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
3
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
4
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
5
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
6 Pomalidomide Approved Phase 3,Phase 2,Phase 1 19171-19-8
7
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
8
Cytarabine Approved, Investigational Phase 3,Phase 1,Phase 2 147-94-4 6253
9
Melphalan Approved Phase 3,Phase 2 148-82-3 460612 4053
10
Anagrelide Approved Phase 3,Phase 2 68475-42-3 2182
11
Iron Approved Phase 3 7439-89-6 23925
12
Danazol Approved Phase 3 17230-88-5 28417
13 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
14 Anti-Infective Agents Phase 3,Phase 1,Phase 2
15 Antiviral Agents Phase 3,Phase 2,Phase 1
16 Interferon-alpha Phase 3,Phase 2,Phase 1
17 interferons Phase 3,Phase 2,Phase 1
18 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
19 Analgesics Phase 3,Phase 2,Phase 1
20 Analgesics, Non-Narcotic Phase 3,Phase 2,Phase 1
21 Anti-Inflammatory Agents Phase 3,Phase 2
22 Anti-Inflammatory Agents, Non-Steroidal Phase 3,Phase 2
23 Antipyretics Phase 3,Phase 2
24 Antirheumatic Agents Phase 3,Phase 1,Phase 2
25 Cyclooxygenase Inhibitors Phase 3,Phase 2
26 Fibrinolytic Agents Phase 3,Phase 2
27 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
28 Platelet Aggregation Inhibitors Phase 3,Phase 2
29 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
30 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
31 Mitogens Phase 3
32 glucocorticoids Phase 3,Phase 2
33 Androgens Phase 3
34 6-Mercaptopurine Phase 3
35 proline Nutraceutical Phase 3,Phase 1,Phase 2
36
Panobinostat Approved, Investigational Phase 1, Phase 2 404950-80-7 6918837
37
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
38
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
39
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2 22916-47-8 4189
40
Arsenic trioxide Approved, Investigational Phase 2,Phase 1 1327-53-3 518740
41
Doxorubicin Approved, Investigational Phase 2,Phase 1 23214-92-8 31703
42
Zoledronic acid Approved Phase 2 118072-93-8 68740
43
alemtuzumab Approved, Investigational Phase 2 216503-57-0
44
Dexamethasone Approved, Investigational, Vet_approved Phase 2 50-02-2 5743
45
Posaconazole Approved, Investigational, Vet_approved Phase 2 171228-49-2 147912
46 Mirabegron Approved Phase 2 223673-61-8
47
Prednisone Approved, Vet_approved Phase 2,Phase 1 53-03-2 5865
48
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
49
Vidarabine Approved, Investigational Phase 2 24356-66-9 21704 32326
50
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316

Interventional clinical trials:

(show top 50) (show all 154)

# Name Status NCT ID Phase Drugs
1 Laser Therapy Prevents Mucositis Oral in Chemotherapy for Bone Marrow Transplantation? Unknown status NCT02020928 Phase 3
2 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
3 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
4 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
5 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
6 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
7 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
8 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
9 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Recruiting NCT02292446 Phase 3 Ruxolitinib
10 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
11 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Active, not recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
12 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Active, not recruiting NCT01243944 Phase 3 ruxolitinib tablets
13 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
14 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
15 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
16 Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Terminated NCT01645124 Phase 3 Hydroxyurea
17 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
18 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
19 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
20 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
21 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
22 Phase II Study of ZIO-101 in Advanced Blood and Bone Marrow Cancers Completed NCT00421213 Phase 2 Darinaparsin
23 The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer) Completed NCT00436059 Phase 2 bortezomib
24 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Completed NCT01193283 Phase 1, Phase 2 Cyclophosphamide;Cyclosporine
25 Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector Completed NCT01428128 Phase 2 Arsenic Trioxide
26 SCIO-469: Open-Label Study for Patients With Myelodysplastic Syndromes. Completed NCT00113893 Phase 2 SCIO-469;SCIO-469;SCIO-469;SCIO-469
27 Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancers Completed NCT01367288 Phase 2 Zometa + Neoadjuvant therapy;Neoadjuvant therapy
28 A Pilot Study of Alemtuzumab (Campath[R]) in Patients With Myelodysplastic Syndrome Completed NCT00217594 Phase 2 Alemtuzumab (Campath)
29 Velcade Consolidation Bone Study Completed NCT01286077 Phase 2 bortezomib
30 Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD Completed NCT00908232 Phase 2 Cyclophosphamide;Bortezomib;Dexamethasone;Lenalidomide
31 Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14) Completed NCT01745640 Phase 2 POMALIDOMIDE;Dexamethasone
32 Pharmacokinetics of Posaconazole Prophylaxis in Acute Leukemia Completed NCT00936117 Phase 2 Posaconazole
33 IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma Completed NCT01053949 Phase 2 Pomalidomide;Pomalidomide
34 A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera Completed NCT01901432 Phase 1, Phase 2 Givinostat
35 Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia Completed NCT01420783 Phase 2 SAR302503
36 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
37 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
38 Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Completed NCT01193699 Phase 1, Phase 2 PEG-P-INF alpha-2b (P1101)
39 Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation Completed NCT02311569 Phase 2 Mirabegron
40 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2 Gleevec
41 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Completed NCT00928707 Phase 2 GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
42 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
43 Momelotinib in Transfusion-Dependent Adults With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF) Completed NCT02515630 Phase 2 MMB
44 Effects of Imatinib Mesylate in Polycythemia Vera Completed NCT00430066 Phase 2 Imatinib Mesylate
45 Study of SB939 in Subjects With Myelofibrosis Completed NCT01200498 Phase 2 SB939
46 Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera Completed NCT00241241 Phase 2 pegylated interferon-alfa 2a
47 Phase 2 Study in Japanese Patients With Intermediate-2 or High Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, Post-Essential Thrombocythemia Myelofibrosis With Splenomegaly Completed NCT01692366 Phase 2 SAR302503
48 A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis Completed NCT00745550 Phase 1, Phase 2 SB1518
49 Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis Completed NCT01445769 Phase 2 Ruxolitinib
50 CC-4047 in Treating Patients With Myelofibrosis Completed NCT00669578 Phase 1, Phase 2 CC-4047

Search NIH Clinical Center for Bone Marrow Cancer

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: myeloproliferative disorders

Genetic Tests for Bone Marrow Cancer

Anatomical Context for Bone Marrow Cancer

MalaCards organs/tissues related to Bone Marrow Cancer:

38
Bone, Bone Marrow, Myeloid, Testes, Breast, Liver, Neutrophil

Publications for Bone Marrow Cancer

Articles related to Bone Marrow Cancer:

# Title Authors Year
1
Mayo breakthrough: virus may destroy bone marrow cancer. ( 25233543 )
2014
2
Erythrokinetics and androgens in bone marrow cancer. ( 975001 )
1976

Variations for Bone Marrow Cancer

ClinVar genetic disease variations for Bone Marrow Cancer:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
2 FGFR3 NM_000142.4(FGFR3): c.1118A> G (p.Tyr373Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121913485 GRCh37 Chromosome 4, 1806099: 1806099
3 INSL6; JAK2 NM_004972.3(JAK2): c.2047A> G (p.Arg683Gly) single nucleotide variant Pathogenic/Likely pathogenic rs1057519721 GRCh37 Chromosome 9, 5078360: 5078360

Expression for Bone Marrow Cancer

Search GEO for disease gene expression data for Bone Marrow Cancer.

Pathways for Bone Marrow Cancer

Pathways related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.07 ABL1 CD177 CSF3 FGFR1 FLT3 IL3
2
Show member pathways
13.86 ABL1 CSF3 EPOR FGFR1 FLT3 IL3
3
Show member pathways
13.75 BCR FGFR1 JAK2 KIT PDGFRA PDGFRB
4
Show member pathways
13.75 EPOR FGFR1 FLT3 IL3 JAK2 KIT
5
Show member pathways
13.66 CSF3 EPO EPOR FGFR1 FLT3 IL3
6
Show member pathways
13.58 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
7
Show member pathways
13.53 EPO EPOR FGFR1 FLT3 IL3 JAK2
8
Show member pathways
13.52 ABL1 FGFR1 IL3 JAK2 KIT PDGFRA
9
Show member pathways
13.43 CSF3 EPOR FGFR1 FLT3 IL3 JAK2
10
Show member pathways
13.39 CSF3 FGFR1 FLT3 IL3 JAK2 KIT
11
Show member pathways
13.35 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
12
Show member pathways
13.35 CSF3 FGFR1 IL3 JAK2 KIT PDGFRA
13
Show member pathways
13.34 ABL1 CD177 GATA1 IL3 JAK2 MPL
14
Show member pathways
13.3 EPOR FGFR1 FLT3 IL3 KIT PDGFRA
15
Show member pathways
13.09 FGFR1 FLT3 IL3 JAK2 KIT PDGFRA
16
Show member pathways
13.08 FGFR1 IL3 KIT PDGFRA PDGFRB THPO
17
Show member pathways
13.08 FGFR1 IL3 JAK2 KIT PDGFRA PDGFRB
18
Show member pathways
13.01 EPOR FGFR1 FLT3 KIT PDGFRA PDGFRB
19
Show member pathways
12.96 CSF3 EPO EPOR FGFR1 FLT3 IL3
20
Show member pathways
12.89 EPO EPOR JAK2 KIT PDGFRA PDGFRB
21
Show member pathways
12.82 ABL1 EPO EPOR JAK2 STAT5A
22
Show member pathways
12.79 JAK2 MPL PTPN11 STAT5A THPO
23
Show member pathways
12.78 ABL1 FGFR1 FLT3 KIT PDGFRA PDGFRB
24 12.77 FGFR1 FLT3 KIT PDGFRA PDGFRB
25
Show member pathways
12.74 FGFR1 KIT PDGFRA PDGFRB PTPN11
26
Show member pathways
12.62 JAK2 PDGFRA PDGFRB PTPN11 STAT5A
27 12.62 GATA1 IL3 JAK2 KIT MPL RUNX1
28 12.49 ABL1 BCR EPO EPOR FGFR1 FLT3
29
Show member pathways
12.41 KIT PDGFRA PDGFRB PTPN11
30
Show member pathways
12.35 FLT3 IL3 JAK2 STAT5A
31 12.21 ABL1 JAK2 PTPN11 STAT5A
32
Show member pathways
12.21 ABL1 BCR PTPN11 RUNX1 STAT5A
33
Show member pathways
12.21 EPO EPOR IL3 JAK2 KIT PTPN11
34
Show member pathways
12.19 BCR FGFR1 STAT5A ZMYM2
35 12.14 GATA1 IL3 PDGFRB RUNX1 THPO
36
Show member pathways
12 IL3 JAK2 PTPN11 STAT5A
37 11.98 CSF3 EPO FLT3 IL3 KIT MPL
38
Show member pathways
11.96 EPO EPOR JAK2 PTPN11 STAT5A
39 11.92 ABL1 BCR FGFR1 FLT3 JAK2 KIT
40
Show member pathways
11.9 BCR FGFR1 STAT5A ZMYM2
41
Show member pathways
11.86 FGFR1 FLT3 KIT PDGFRB
42 11.86 ABL1 EPO EPOR IL3 JAK2 PTPN11
43 11.85 FGFR1 PDGFRA PDGFRB
44 11.79 CSF3 EPO EPOR FLT3 IL3 KIT
45 11.77 JAK2 PTPN11 STAT5A
46 11.75 FGFR1 FLT3 KIT PDGFRA PDGFRB
47
Show member pathways
11.74 CSF3 EPO EPOR IL3 JAK2 MPL
48
Show member pathways
11.71 ABL1 BCR KIT PDGFRA PDGFRB
49 11.66 ABL1 PDGFRB PTPN11 STAT5A
50 11.57 JAK2 PDGFRB STAT5A

GO Terms for Bone Marrow Cancer

Biological processes related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show all 46)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 ABL1 EPO PDGFRA PDGFRB PTPN11 THPO
2 brain development GO:0007420 9.98 BCR EPOR FGFR1 PTPN11
3 regulation of cell proliferation GO:0042127 9.97 ABL1 FGFR1 JAK2 KIT
4 positive regulation of cell migration GO:0030335 9.94 JAK2 KIT PDGFRA PDGFRB
5 phosphatidylinositol phosphorylation GO:0046854 9.93 FGFR1 KIT PDGFRA PDGFRB PTPN11
6 positive regulation of protein kinase B signaling GO:0051897 9.91 CSF3 FGFR1 KIT PDGFRA PDGFRB PTPN11
7 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.9 FLT3 KIT PDGFRA PDGFRB
8 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.89 ABL1 CSF3 GATA1 IL3 JAK2
9 positive regulation of MAP kinase activity GO:0043406 9.88 FGFR1 FLT3 KIT PDGFRB
10 regulation of hematopoietic stem cell differentiation GO:1902036 9.87 ABL1 GATA1 RUNX1
11 positive regulation of MAPK cascade GO:0043410 9.87 FGFR1 FLT3 KIT
12 erythrocyte differentiation GO:0030218 9.87 EPO GATA1 JAK2 KIT
13 cytokine-mediated signaling pathway GO:0019221 9.87 CSF3 EPOR FLT3 IL3 JAK2 KIT
14 protein autophosphorylation GO:0046777 9.86 ABL1 BCR FGFR1 FLT3 JAK2 KIT
15 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.85 EPO FLT3 IL3 JAK2 KIT
16 hemopoiesis GO:0030097 9.84 FLT3 KIT RUNX1
17 cell chemotaxis GO:0060326 9.84 KIT PDGFRA PDGFRB
18 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.83 FLT3 KIT PDGFRA PDGFRB
19 phosphatidylinositol-mediated signaling GO:0048015 9.81 FGFR1 PDGFRA PDGFRB
20 positive regulation of DNA replication GO:0045740 9.8 EPO IL3 PDGFRA
21 embryonic hemopoiesis GO:0035162 9.77 GATA1 IL3 KIT
22 positive regulation of phospholipase C activity GO:0010863 9.71 FGFR1 KIT PDGFRA PDGFRB
23 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.7 JAK2 STAT5A
24 negative regulation of cell-cell adhesion GO:0022408 9.69 ABL1 JAK2
25 cellular response to thyroid hormone stimulus GO:0097067 9.69 GATA1 KIT
26 positive regulation of phosphoprotein phosphatase activity GO:0032516 9.68 JAK2 PDGFRB
27 cardiac myofibril assembly GO:0055003 9.68 PDGFRA PDGFRB
28 dendritic cell differentiation GO:0097028 9.68 FLT3 GATA1
29 positive regulation of osteoblast proliferation GO:0033690 9.67 ABL1 GATA1
30 retina vasculature development in camera-type eye GO:0061298 9.66 PDGFRA PDGFRB
31 Bergmann glial cell differentiation GO:0060020 9.65 ABL1 PTPN11
32 regulation of cytokine-mediated signaling pathway GO:0001959 9.65 IL3 RUNX1
33 negative regulation of platelet-derived growth factor receptor-beta signaling pathway GO:2000587 9.65 PDGFRA PDGFRB
34 erythropoietin-mediated signaling pathway GO:0038162 9.65 EPO EPOR KIT
35 myeloid progenitor cell differentiation GO:0002318 9.64 FLT3 KIT
36 platelet-derived growth factor receptor signaling pathway GO:0048008 9.63 ABL1 BCR JAK2 PDGFRA PDGFRB PTPN11
37 metanephric glomerular capillary formation GO:0072277 9.62 PDGFRA PDGFRB
38 platelet-derived growth factor receptor-beta signaling pathway GO:0035791 9.62 ABL1 PDGFRB
39 thrombopoietin-mediated signaling pathway GO:0038163 9.61 MPL THPO
40 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.61 PDGFRA PDGFRB
41 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.5 CSF3 FGFR1 FLT3 JAK2 KIT PDGFRA
42 peptidyl-tyrosine phosphorylation GO:0018108 9.36 ABL1 BCR FGFR1 FLT3 IL3 JAK2
43 phosphorylation GO:0016310 10.16 ABL1 BCR FGFR1 FLT3 JAK2 KIT
44 protein phosphorylation GO:0006468 10.15 ABL1 BCR FGFR1 FLT3 JAK2 KIT
45 positive regulation of cell proliferation GO:0008284 10.09 CSF3 EPO FGFR1 FLT3 IL3 JAK2
46 MAPK cascade GO:0000165 10.05 FGFR1 IL3 JAK2 KIT PDGFRA PDGFRB

Molecular functions related to Bone Marrow Cancer according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 kinase activity GO:0016301 9.92 ABL1 BCR FGFR1 FLT3 JAK2 KIT
2 protein kinase activity GO:0004672 9.91 ABL1 FGFR1 FLT3 JAK2 KIT PDGFRA
3 nucleotide binding GO:0000166 9.89 FGFR1 JAK2 KIT PDGFRA PDGFRB
4 cytokine activity GO:0005125 9.81 CSF3 EPO IL3 THPO
5 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.65 FGFR1 KIT PDGFRA PDGFRB PTPN11
6 cytokine receptor activity GO:0004896 9.61 EPOR FLT3 MPL
7 platelet-derived growth factor receptor binding GO:0005161 9.58 PDGFRA PDGFRB
8 platelet-derived growth factor binding GO:0048407 9.56 PDGFRA PDGFRB
9 insulin receptor substrate binding GO:0043560 9.55 JAK2 PTPN11
10 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.55 FGFR1 FLT3 KIT PDGFRA PDGFRB
11 peptide hormone receptor binding GO:0051428 9.52 JAK2 PTPN11
12 vascular endothelial growth factor-activated receptor activity GO:0005021 9.48 FLT3 PDGFRA
13 vascular endothelial growth factor binding GO:0038085 9.46 PDGFRA PDGFRB
14 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.43 FGFR1 IL3 JAK2 KIT PDGFRA PDGFRB
15 protein tyrosine kinase activity GO:0004713 9.36 ABL1 BCR FGFR1 FLT3 IL3 JAK2
16 protein binding GO:0005515 10.47 ABL1 BCR CD177 EPO EPOR FGFR1
17 transferase activity GO:0016740 10.17 ABL1 BCR FGFR1 FLT3 JAK2 KIT
18 ATP binding GO:0005524 10.06 ABL1 BCR FGFR1 FLT3 JAK2 KIT

Sources for Bone Marrow Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....